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Plasmacytoid dendritic cells (pDCs) are a specialized subset of DCs that links innate and
adaptive immunity. They sense viral and bacterial pathogens and release high levels of
Type I interferons (IFN-I) in response to infection. pDCs were shown to contribute to
inflammatory responses in the steady state and in pathology. In atherosclerosis, pDCs
are involved in priming vascular inflammation and atherogenesis through production
of IFN-I and chemokines that attract inflammatory cells to inflamed sites. pDCs also
contribute to the proinflammatory activation of effector T cells, cytotoxic T cells,
and conventional DCs. However, tolerogenic populations of pDCs are found that
suppress atherosclerosis-associated inflammation through down-regulation of function
and proliferation of proinflammatory T cell subsets and induction of regulatory T cells with
potent immunomodulatory properties. Notably, atheroprotective tolerogenic DCs could be
induced by certain self-antigens or bacterial antigens that suggests for great therapeutic
potential of these DCs for development of DC-based anti-atherogenic vaccines.
Keywords: plasmacytoid dendritic cell, conventional dendritic cell, innate immunity, type I interferon,
inflammation, tolerance, atherosclerosis
INTRODUCTION
Atherosclerotic arterial disease is a chronic cardiovascular pathol-
ogy commonly associated with heart attack and stroke, both
are leading causes of mortality in developed countries. Various
cardiometabolic risk factors including biased plasma levels of
lipoproteins could induce endothelial dysfunction progressing
to preclinical atherogenesis even early in life (Morrison et al.,
2013). Entrance and accumulation of plasma lipids (andmodified
lipoproteins especially) in the arterial wall launches the adaptive
immune response. Blood-borne immune cells infiltrate intimal
regions enriched with lipids. Although macrophages and some
dendritic cells (DCs) reside in the arterial wall, increased influx
of extravasated monocytes is thought to be the major trigger of
inducing the inflammatory response in affected intima media
(Ley et al., 2011). In the intima media, monocytes acquire a phe-
notype that is consistent with inflammatory macrophages and
inflammatory DCs and is influenced by load of modified lipids,
cytokines, chemokines, and hematopoietic growth factors. Due to
the proinflammatory switch in the local microenvironment, res-
ident macrophages and DCs also change their phenotype (Lech
et al., 2012).
Along with monocytes and macrophages, DCs play a key role
in early stages of atherosclerotic inflammation and in advanced
stages of atherosclerosis (Bobryshev and Lord, 1998; Bobryshev,
2010). DCs are professional antigen-presenting cells (APCs)
involved in the induction of T cell-mediated adaptive immunity
through the recruitment of naïve T cells. However, in athero-
genic proinflammatory conditions, the normal adaptive immune
response becomes maladaptive. A variety of DC subsets is present
in lymphoid and non-lymphoid organs. Twomajor DC subpopu-
lations include conventional DCs (cDCs) and plasmacytoid DCs
(pDCs) (Miloud et al., 2010). During inflammation, an addi-
tional DC subset has been described, so-called inflammatory
DCs, which differentiate from monocytes recruited to the site
of inflammation (Segura and Amigorena, 2013). In this review,
we highlight the recent information about the development and
functions of pDCs as well as role of this subtype of DCs in
atherosclerotic inflammation.
DEVELOPMENT OF pDCs
The classical hematopoietic model states the segregation of lym-
phoid and myeloid lineages at earliest stages of hematopoiesis.
In early studies, murine cDCs and pDCs were suggested to
develop through either the myeloid or the lymphoid pathway
of hematopoiesis (Diao et al., 2004). However, accumulated evi-
dence indicates that the origin of human DCs is markedly dif-
ferent from that of murine DCs. An existence of a common DC
precursor was suggested for human cDCs and pDCs (Ishikawa
et al., 2007). In mice, Naik et al. (2007) then reported find-
ing unique CD11c−MHCII− DC progenitors that differentiate
to CD11c+MHCII- DC precursors further generating the three
distinct CD11c+MHCII+ DC subtypes (pDCs, CD8+ cDCs,
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and CD8− cDCs). Both murine DC progenitors were shown to
express surface fms-like tyrosine kinase 3 (Flt3), a receptor for the
hematopoietic growth factor Flt3 ligand (Naik et al., 2010).
CD11c−MHCII−Flt3+ DC precursors seem to represent
common myeloid progenitors (CMPs) that differentiate to DC-
restricted MHCII-Flt3+ DC progenitors expressing colony-
stimulating factor 1 receptor (CSF1R) and capable to produce
both cDCs and pDCs (Onai et al., 2007) (Figure 1). Macrophage-
colony-stimulating factor (M-CSF) was shown to bind to CSF1R
and drive differentiation of both cDCs and pDCs in mice
(Fancke et al., 2008). DC-restricted MHCII-Flt3+ DC progeni-
tors then differentiate into the common CD11c+MHC−II− cDC-
restricted precursors (called pre-DCs) further producing CD8+
and CD11b+ cDCs (Diao et al., 2006; Naik et al., 2006). Common
lymphoid DC progenitors (CLPs) were found in the mouse bone
marrow (D’Amico and Wu, 2003; Sathe et al., 2013). According
to the study of Sathe et al. (2013), CLPs produced only a few
cDCs with variable efficiency, but produced pDCs via a tran-
sient intermediate precursor with B-cell potential. pDCs of CLP
origin showed evidence of past recombination activating gene
(RAG)-1 expression and had D-J IgH gene rearrangements sug-
gesting for their lymphoid past (Corcoran et al., 2003; Pelayo
et al., 2005). Differentiation of CMPs resulted in a heteroge-
neous population of pDCs. Most pDCs of CMP origin did not
show signs of a lymphoid past. However, some pDCs of CMP
origin exhibited evidence of past RAG1 expression and had D-J
IgH gene rearrangements (Sathe et al., 2013). Some CMP-derived
pDCs were without such IgH gene rearrangements. Finally, some
pDC-like cells did not express key pDC markers such as C-C
chemokine receptor (CCR)-9 but produced interferon (IFN)-
α, a characteristic of the pDC subset (Shortman et al., 2013).
Upon stimulation with CpG oligonucleotides, pDCs of both CLP
and CMP origin secreted IFN-α. Indeed, both pDCs and cDCs
could be convergently generated from the lymphoid and myeloid
precursors.
Like mouse pDCs, human pDCs could be convergently
produced from the lymphoid (granulocyte-macrophage) and
multi-myeloid progenitors (MLPs) that are distinct from the
FIGURE 1 | Differentiation of mouse plasmacytoid dendritic cells (pDCs)
from hematopoietic stem cells (HSCs) or lymphoid-primed multipotent
progenitors (LPMPs). Bone-marrow hematopoiesis is a multistep process
involving sequential generation of common lymphoid progenitors (CLPs),
common myeloid progenitors (CMPs), megakaryote-erythroid progenitors
(MEPs), granulocyte-macrophage progenitors (GMPs), macrophage dendritic
cell progenitors (MDPs), common dendroid cell progenitors (CDP), and
conventional dendritic cell precursors (pre-cDCs). Generally, MDPs and CDPs
preferentially differentiate to cDCs and produce few pDCs. However, two
subsets of pDC precursors (Lin−c-kitint/lowCD115−CD135+ and
CCr9−Bst2+SiglecH+) with high potential to differentiate to pDCs were
found. These subsets could be generated from either from CDPs or early
lymphoid progenitors (LPMPs, CLPs) suggesting for the existence of the
alternate mechanisms of pDC differentiation in mice. Phenotypes of
hematopoietic progenitors are presented. Growth factors and cytokines
stimulating hematopoietic differentiation are shown near arrows.
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conventional myeloid or lymphoid pathway (Ishikawa et al.,
2007). Consistent with this, mutation in GATA2, a key
hematopoietic transcription factor fully abolishes population of
human MLPs and results in complete lack of DCs (Collin et al.,
2011). Flt3 ligand in synergy with GM-CSF, IL-4, and tumor
necrosis factor (TNF)-α was shown to act as a potent inducer of
myeloid DC precursors from hematopoietic precursors. Myeloid
precursors could be then clonally expanded in the presence of Flt3
ligand, GM-CSF, and thrombopoietin (TPO). Finally, Flt3 ligand
supports further maturation of myeloid precursors to functional
CD1a+ DC precursors (Harada et al., 2007).
However, compared to the knowledge about differentiation of
mouse pDCs, the developmental stages of different DC subsets
in humans remain poorly defined (Schotte et al., 2010). To date,
human equivalents of mouse macrophage dendritic cell progeni-
tor (MDP), commonDC progenitor (CDP), and pre-DC have not
been found. Compared to mouse DC precursors, human CD34+
hematopoietic stem cells (HSCs) express major histocompatibil-
ity complex (MHC) class II (Majumdar et al., 2003). This indeed
hampers the identification of early DC precursors in human
blood. In contrast to human cDCs that could proliferate, pDCs
do not proliferate suggesting that human pDCs leave the bone
marrow fully differentiated (Randolph et al., 2008). Comparison
of genome-wide expression profiles clearly cluster human pDCs
with mouse pDCs with sharing a large gene expression program
shared between those cells (Robbins et al., 2008). That should
be helpful in further finding similarities and differences in the
developmental programs of human and mouse pDCs.
Depending on the stimuli, DC progenitors are able to
develop DCs with different phenotypes. For example, culturing
mouse DC progenitors with granulocyte-macrophage colony-
stimulating factor (GM-CSF) and interleukin (IL)-4 resulted in
generating inflammatory Mac3+CD11b+CD24+ DCs express-
ing large amounts of tumor necrosis factor (TNF)-α, IL-10,
chemokine (C-C motif) ligand (CCL)-2, and nitric oxide (NO).
Unlike GM-CSF/IL-4-induced DCs, Flt3-induced DCs produced
no TNF-α, IL-10, or CCL-2. Further investigations showed that
GM-CSF/IL-4-induced DCs correspond to TNF-α- and NO-
producing proinflammatory DCs while FLt3-induced DCs are
equivalents of the steady-state resident DCs (Xu et al., 2007).
These finding showed that local microenvironment could play a
critical role in driving the terminal phenotype of DCs. Indeed,
vascular inflammation presented in atherosclerotic lesions will
favor for differentiation of circulating DC progenitors and pre-
cursors toward the proinflammatory DCs.
TRANSCIPTION AND GROWTH FACTORS DRIVING
DIFFERENTIATION OF pDCs
As mentioned above, common myeloid and lymphoid DC pro-
genitors were found in mice and humans. However, since the
DC differentiation program is studied much better in mice than
in humans, we will focus on murine transcription and growth
factors that are involved in DC development.
MDPs precede differentiation of myeloid progenitors to the
mononuclear phagocyte lineage in hematopoiesis (Fogg et al.,
2006). MDPs produce spleen macrophages, cDCs resided in the
lymphoid and non-lymphoid tissue, and a few pDCs (Merad
et al., 2013). MDPs have the following phenotype: Lin−Sca1−
IL-7Rα−CD116−/32hic-kit+CX3CR+CD11b−CD115+CD135+
(Fogg et al., 2006). The precursors are negative for stem cell
markers Lin and Sca1, both are essential for maintenance and
self-renewal of HSCs (Kumar et al., 2008), but still express c-kit
(or CD117), another surface marker of HSCs. In addition, MDPs
express some lymphoid lineage-specific markers such as CX3CR
(receptor for fractalkine CX3CL1 that regulates adhesion and
migration of lymphocytes) but lose the receptor for IL-7, a
cytokine driving development of B cells. MDPs highly express
myeloid lineage-specific markers such as CD16/32 (Fc receptors)
and CD115 (M-CSF receptor) and start to express Flt3 (CD135),
a DC-specific marker. At that stage, hematopoietic growth factors
such as GM-CSF, M-CSF, and Flt3 ligand are essential to regulate
commitment of mononuclear phagocytes and DC precursors
(Stanley et al., 1997; Karsunky et al., 2003; Fancke et al., 2008).
In fact, GM-CSF is a critical factor for general DC development
under both steady-state and inflammatory conditions including
GM-CSF-mediated activation of key signaling modules such as
Jak/Stat, Mapk, Pi3k, and NF-κB that support cell growth and
proliferation (van de Laar et al., 2012).
In an MDP, expression of lineage-specific transcription factors
such as nuclear factor, interleukin 3 regulated (Nfil3) and inter-
feron regulatory factor-8 (Irf8) is induced to initiate transcrip-
tional programs regulating differentiation toward mononuclear
phagocytes and CD8α+ cDCs (Wang and Morse, 2009; Becker
et al., 2012; Male et al., 2012). Nfil3 is required for CD8α+ cCD
development since Nfil3-deficient mice specifically lack CD8α+
cCDs but not CD8α− cCDs and pDCs (Kashiwada et al., 2011).
Transcription factor PU.1 (spleen focus forming virus proviral
integration oncogene; Spi1) is essential for chromatin structure
remodeling in the promoter of the Irf8 gene to activate a lineage-
and developmental-stage-specific cis-enhancer to prevent MDP
reprogramming toward the myeloid lineage and induce DC-
specific differentiation (Schönheit et al., 2013). In the absence
of PU.1, MDP spontaneously differentiate to neutrophils. Irf8 is
crucial for the development of CD8α+ cDCs mediated by tran-
scription factors such as DNA-binding protein inhibitor (Id2) and
basic leucine zipper transcription factor, ATF-like (Batf3) In the
absence of Id2 and Batf3, Irf8 supports preferential differentiation
of DC precursors to pDCs (Jaiswal et al., 2013).
After commitment of the mononuclear phagocyte lineage,
MDPs differentiate to CDPs that phenotypically are as follows:
Lin−Sca1−IL-7Rα−CD16/32lowc-kitintCD11b−CD115+CD135+.
Compared to MDPs, CDPs have decreased expression of the
myeloid lineage marker CD16/32 but hold expression of both
CD115 and CD135 necessary for further differentiation and
maintenance of DC-specific lineage properties (Naik et al., 2007;
Onai et al., 2007). CDPs have increased expression of Ret3, a
surface marker specific for DCs and follicular macrophages
(follicular DCs) (Nagasaki et al., 1995). Hematopoietic growth
factors (GM-CSF, M-CSF, and Flt3 ligand) are required to
support differentiation of MDPs to DCs.
Compared to MDPs, expression of the DC lineage-
supporting transcription factors such as Nfil3, Irf8, PU.1, signal
transducer and activator of transcription (Stat5b), B-cell lym-
phoma/leukemia 11A (Bcl11a), and Runt-related transcription
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factor 2 (Runx2), is up-regulated in CDPs (Murphy, 2013).
Bcl11a contributes to DC development through activation of
expression of Flt3 in early hematopoietic precursors (Wu et al.,
2013). Bcl11a is considered as a pDC-specific marker (Pulford
et al., 2006; Marafioti et al., 2008) especially critical for commit-
ment of pDCs since it regulates transcription of E2-2 (also known
as transcription factor-4; Tcf4) and other DC differentiation
modulators including Id2 and core-binding factor, Runt-domain,
α-subunit 2, translocated to, 3 (Cbfa2t3/Mtg16) (Ippolito et al.,
2014). In Bcl11a-deficient mice, numbers of pDCs were markedly
decreased and development of cDCs was impaired (Wu et al.,
2013).
PU.1, an ETS family transcription factor, is required for sup-
porting preferential commitment of common DC precursors
from common myeloid precursors (Carotta et al., 2010) and
induction of expression of CD11c, a specific surface marker of
pDCs in DC precursors (Zhu et al., 2012). However, PU.1 is not a
transcription factor that supports predominant differentiation of
DC precursors to pDC. In support of this, Schlitzer et al. (2011)
showed the ability of CCR9−MHCIIlow pDCs, which are imme-
diate precursors of fully differentiated CCR9+ pDCs, to switch
maturation to CD11b+CD8−MHCIIhigh cDCs in the presence of
GM-CSF that down-regulates E2-2 and up-regulates PU1.2, Id2,
and Batf3.
In Runx2-deficient mice, pDCs developed normally in the
bone marrow but were greatly reduced in the periphery sug-
gesting that Runx2 is essential for terminal differentiation of
peripheral pDCs. Runx2 was required for the expression of sev-
eral pDC-enriched genes including the chemokine receptors Ccr2
and Ccr5 (Sawai et al., 2013). Finally, Stat5b and other members
of the Stat family of transcriptional coactivators mediate GM-
CSF-mediated stimulating effects on DC growth and terminal
differentiation (Bontkes et al., 2006). In murine DCs and DC
precursors, GM-CSF was shown to induce a unique set of the
Stat family of signal transducers including Stat5b that in turn
form heterodimeric signaling complexes to mediate GM-CSF-
dependent signaling cascades (Welte et al., 1997). Stat5b supports
diversification from CDPs toward cDCs by inhibiting pDC devel-
opment. The Stat3/Stat5 signaling complex stimulates GM-CSF-
mediated suppression of pDC-specific transcription factor E2-2
and supports induction of Id2 (Li et al., 2012). In addition, Stat5b
suppresses GM-CSF-dependent generation of pDCs (Gilliet et al.,
2002) through inhibition of Irf8 (Esashi et al., 2008). Stat5 also
controls terminal differentiation of DCs at late developmental
stages (van de Laar et al., 2011).
CDPs then give rise to pDCs and pre-DCs that are precur-
sors of CD8+ and CD11b+ cDCs. In Flt3+ pDCs, expression
of receptors for GM-CSF and M-CSF is down-regulated (Merad
et al., 2013) since GM-CSF does not supports terminal differen-
tiation of pDCs. However, M-CSF could drive development of
both pDCs and cDCs from bone marrow-derived precursors in
Fcl3-deficient mice suggesting that Flt3 is the archetypal DC poi-
etin in the steady state (O’Keeffe et al., 2010). In Flt3-deficient
mice, reduced numbers ofMDPs and CDPs are remained. Indeed,
Flt3 deficiency may restrict the ability of other growth factors to
drive DC development by limiting the pool of progenitor cells
available.
Type I IFNs (IFN-I) and Flt3 ligand could act synergistically to
support pDC development (Chen et al., 2013). Flt3 ligand induces
IFN-I expression in CLPs. IFN-I in turn activates Flt3 production
in CLPs thereby enhancing CLP proliferation and differentiation
to pDCs. On the surface, pDCs highly express IFN-α receptor
(Ifnar) consisting of two chains (Ifnar1 and Ifnar2) and essential
for binding IFN-I that are crucial for terminal maturation and
steady-state function of pDCs (Gauzzi et al., 2002; Toma-Hirano
et al., 2007).
Fully differentiated murine pDCs express a unique combina-
tion of surface markers including CD11c, B220, Ly6C/G, and
Ly49Q (Omatsu et al., 2005). CD11c (or integrin αX) is expressed
not only on pDCs but also on cDCs, monocytes, macrophages,
and some B cells (Stewart et al., 1996). CD11c combines with
the β2 chain (ITGB2; CD18) to form a leukocyte-specific inte-
grin referred to as inactivated-C3b (iC3b) receptor 4 (CR4;
CD11c/CD18), which binds a variety of ligands that regulate pDC
adhesion and motility (Piemonti et al., 1999). B220 is a sur-
face receptor protein tyrosine phosphatase C (PtprcC or CD45)
involved in the regulation of T- and B-cell antigen receptor sig-
naling. In CD45-deficient mice, DCs had impaired capacity to
produce IFN-I in response to lymphocytic choriomeningitis virus
infection suggesting that CD45 is involved in the control of IFN-I
production in pDCs (Montoya et al., 2006).
Expression of Ly49Q, a lectin-type killer cell inhibitory recep-
tor, is induced by IFN-I (Toma-Hirano et al., 2007). On the
other hand, Ly49Q is also involved in the regulation of IFN-
I production by enhancing Toll-like receptor-9 (Tlr9)-mediated
signaling in pDCs (Rahim et al., 2013). On pDCs, Ly49Q was
shown to bind H-2Kb, a classical MHC class I molecule (Tai et al.,
2007), which enhances pDC function (Tai et al., 2008). Ly49Q
also binds the Ly49Q ligand that stimulates maturation of pDCs
(Toma-Hirano et al., 2009). Lack of Ly49Q expression defines two
subsets of pDCs (Ly49Q+ and Ly49Q− DCs) (Kamogawa-Schifter
et al., 2005). Cultured Ly49Q− cells are able to spontaneously
up-regulate Ly49Q without cell proliferation and acquire most
properties of typical pDCs. Upon stimulation with CpG oligonu-
cleotides or Sendai virus, Ly49Q− pDCs upregulate expression of
CD86 and MHC class II but produce less IFN-I, IL-6, and IL-
12 compared to Ly49Q+ pDCs (Omatsu et al., 2005). Therefore,
Ly49Q− cells represent less potent and less differentiated subset
of pDCs.
Compared to CDPs, a variety of transcription factors and
transcription regulators responsible for cell type-specific com-
mitment is up-regulated in pDCs. Those include Bcl11a, Runx2,
PU.1, E2-2, Spi-B, Irf4, Ifr8, and Stat3 (Seillet and Belz, 2013)
(Table 1). In contrast, expression of Id2 and Nfil3 essential
for diversification of common DC precursors is suppressed. In
pDCs, expression of transcription factors such as Bcl6, Zbtb46,
and Barf3 involved in cDC-specific differentiation is also down-
regulated. E2-2 is highly expressed in human and mouse pDCs
(Cisse et al., 2008). Deletion of E2-2 in mice results in lack of
pDCs that suggests for specific role of this factor in the devel-
opment of pDCs. E2-2 was found to be involved in activation
of many pDC-enriched genes including transcription factors
involved in pDC development (SpiB, Irf8) and function (Irf7)
(Cisse et al., 2008). Spi-B, a PU.1-related transcription factor, is
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Table 1 | Expression of transcription regulators and receptors
essential for differentiation of mouse DCs and their progenitors
(precursors).
Cell Surface receptors Transcription regulators
GMP Clec12a+++ C-kit++
Il3ra++
Stat5a+ Stat5b+
MDP Clec12a++ C-kit++ Flt3+
Ccr2+ Cx3cr1+ Ifnar2+
Csf1r+
Nfil3+ Irf8+
CDP Clec12a+ C-kit+ Flt3++
Ccr2+ Cx3cr1+ Ifnar2++
Csf1r+ Cd209+
Stat5b+ Nfil3++ Bcl11a++
Runx2++ Sfi1/PU.1++ Irf8+
Tcf4/2E-2+ Id2+ Zbtb46+
Spi-B+ Bcl6+
Pre-cDC Clec12a+Cx3cr1+ Scf2ra++
Csf2rb+++ Csf2rb2+
Cxcl9++ Cxcl16+ Ifngr1++
Ly75+ Dxd58+ Tlr13+ Tlr3+
Stat5b+++ Stat3+
Bcl11a+++ Runx2+
Tcf4/2E-2+++ Spi-B+++
Irf8+++ Bcl6+ Irf4+++
Zbtb46+++
pDC Clec12a+++ Tlr7+++
Tlr9+++ Flt3++ Csf2rb++
Csf2rb2+++ Ifnar1+++
Ifnar2+++ Il7r+++
Cx3cr1+++ Ccr9+++
Ccr2+ Siglech+++
Stat3++ Bcl11a+++
Runx2+++ Tcf4/2E-2+
Spi-B+++ Irf8+++
Irf4+++
Data are adopted from Robbins et al. (2008) and Merad et al. (2013). The
expression strength is indicated by the number of plus. Bcl, B-cell lymphoma;
Ccr, C-C chemokine receptor; Cd209, cluster of differentiation 209, Dendritic
Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin(GC-SIGN);
C-kit, tyrosine-protein kinase Kit; Slec, C-type lectin domain; Csf1r, Colony stim-
ulating factor 1 receptor; Cx3cr1, CX3C chemokine receptor 1; Cxcl, Chemokine
(C-X-C motif) ligand; Dxd58, DEAD (Asp-Glu-Ala-Asp) box polypeptide 58; Id2,
DNA-binding protein inhibitor 2; Flt3, Fms-like tyrosine kinase 3; Ifnar, interferon-
α/β receptor; Ifngr1, interferon-γ receptor 1; Il3ra, interleukin-3 receptor, α-chain;
Il7r, interleukin-7 receptor; Irf, Interferon regulatory factor; Ly75, Lymphocyte
antigen 75; Nhil3, nuclear factor, interleukin-3 regulated 3; Runx2, Runt-related
transcription factor 2; Siglech, Sialic acid-binding immunoglobulin-type lectin H;
Stat, Signal transducer and activator of transcription; Sfi1, transcription factor
PU.1; Spi-B, transcription factor (PU.1-related) Spi-B; Tcf4, transcription factor 4;
Tlr, Toll-like receptor; Zbtb46, Zinc finger and BTB domain-containing protein 46.
overexpressed in immediate pDC precursors and is able to sup-
port the development of myeloid lineage in PU.1-deficient mice
(Dahl et al., 2002). However, Spi-B does not express in lymphoid
cells (neuthrophils and monocytes) (Chen et al., 1995) because it
prevents differentiation of hematopoietic progenitor cells toward
the lymphoid lineage (Schotte et al., 2003). Spi-B is critical for
development and function of both mouse (Sasaki et al., 2012)
and human (Schotte et al., 2004) pDCs. E2-2 and Spi-B coop-
erate in stimulating pDC differentiation in order to overcome Id2
enforced block in pDC development (Nagasawa et al., 2008). In
synergy with IRF7, Spi-B activates expression of IFN-I in pDCs
(Sasaki et al., 2012). Finally, Spi-B supports survival of pDCs and
their precursors by up-regulating expression of anti-apoptotic
protein Bcl2-A1 (Karrich et al., 2012).
Compared to pre-DCs, Irf4 is significantly less up-regulated in
pDCs (Robbins et al., 2008). Although Irf4 and Irf8 cooperatively
act in supporting DC differentiation and share many overlap-
ping activities (Yamamoto et al., 2011), Irf4 appears to prefer-
entially support the development of CD4+CD11b+ cDCs while
Irf8 is more focused on stimulating polarization of DC precur-
sors toward pDC phenotype (Vander Lugt et al., 2014). Irf4 and
Irf8 are differently regulated by GM-CSF, which suppresses Irf8
while promoting Irf4 expression (Esashi et al., 2008). In pre-DCs
and cDCs, Irf4 target sequences are enriched with activating pro-
tein 1 (AP-1)-IRF composite elements (AICEs) capable to bind
with Irf4/Batf3 complexes that further drive their transcription
(Glasmacher et al., 2012). Compared to pre-DCs, Stat3/Stat5b
ratio is skewed to Stat3 in pDCs since Stat3 supports terminal dif-
ferentiation of CDP to pDCs whereas Stat5b expression promotes
development toward cDCs (Cohen et al., 2008).
MDPs and CDPs generally produce large amounts cDCs and
only few pDCs. Interestingly, Onai et al. (2013) reported iden-
tification of a Lin−c-kitint/lowCD115−CD135+ progenitor with
great capacity to differentiate predominantly to pDCs. In contrast
to MDPs and CDPs in which expression of E2-2 is down-
regulated, the progenitor expressed high levels of E2-2, an essen-
tial transcription factor for pDC development. The progenitors
could be derived from either CDPs or lymphoid-primedmultipo-
tent progenitors (LMPPs) (Figure 1). Indeed, these findings could
suggest for an alternative mechanism of the development of pDCs
that should be further studied (Shortman and Sathe, 2013).
pDC LOCATION AND TRAFFICKING
DCs leave the bone marrow to give rise to resident and migra-
tory DCs. In the lymphoid tissue, DCs present lymph- and
blood-derived antigens to local T cells. Non-lymphoid tissue DCs
permanently migrate from peripheral tissues to lymph nodes to
present tissue-derived antigens to naïve T cells (Boltjes and van
Wijk, 2014). Under homeostatic conditions, human and mouse
pDCs are mainly resident cells. They are confined to primary
and secondary lymphoid organs (lymph nodes, spleen). Unlike
cDCs that reach the lymph node through afferent lymphatic
vessels, pDCs and their precursors enter lymph nodes directly
from the blood via endothelial venules (Segura et al., 2012). The
migration of pDCs to lymphoid tissue is promoted by expres-
sion of L-selectin (non-inflamed states) or E-selectin (inflamed
states) in high endothelial venules (Yoneyama et al., 2004). CCR7
highly expressed at the surface of pDCs triggers migration toward
increased concentration gradient of its ligands CCL9 and CCL21
abundantly secreted by lymph nodes and then essentially con-
tributes to maintaining pDC homing in lymph nodes (Seth et al.,
2011). In the steady-state, resident pDCs express on the surface
low levels of chemotactic molecules such as CXCR3, CXCR4,
and chemokine receptor-like 1 (CMKLR1 or ChemR23) (Sozzani
et al., 2010) that limits their motility.
In contrast to the current model of pDC development sug-
gesting that mouse pDCs become fully differentiated in the bone
marrow and then migrate to the periphery, Schlitzer et al. (2012)
recently isolated a subset of circulating Ccr9− pDC-like pre-
cursors from the mouse blood capable to differentiate either to
pDCs or cDCs depending on the tissue. Adoptive transfer of
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these precursors to irradiatedmice resulted in formation of Ccr9+
pDCs in the bone marrow and liver whereas in peripheral lym-
phoid organs, lung and intestine the precursors additionally gave
rise to cDCs. The Ccr9- pDC-like precursors could be generated
from CDP both in vivo and in vitro and able to migrate from
the bone marrow to the peripheral lymphoid and non-lymphoid
organs.
Compared to CDPs, the precursors expressed increased lev-
els of pDC-lineage major transcription factors such as E2-2
and Sci-B and pDC-specific surface markers such as sialic acid-
binding IgH-like lectin H (Siglec-H) and bone marrow stromal
cell antigen Bst-2 (Blasius et al., 2006a,b) like terminally dif-
ferentiated Ccr9+ pDCs. Interestingly, Ccr9− pDC-like precur-
sors found by Schlitzer et al. (2012) share some functional and
phenotypical properties with Lin−c-kitint/lowCD115−CD135+
cells (Onai et al., 2013) including high potential to generate
pDCs, elevated expression of E2-2, and capacity to be pro-
duced from CDPs but represent distinct pDC precursor pools.
Indeed, pDCs precursors are likely to form a heterogeneous
population. In contrast to Ccr9+ pDCs, Ccr9− pDC-like pre-
cursors show flexibility to give rise other DCs subsets in a
tissue-specific manner suggesting for the role of the local tis-
sue microenvironment in determining the developmental fate
of pDCs precursors in the peripheral organs. These local stim-
uli should be characterized in the future. The unique combi-
nation of soluble factors including M-CSF, Flt3 ligand, TPO,
IL-3, and IFN-α (Chen et al., 2004; Demoulin et al., 2012) and
unknown cell-bound factors is likely to contribute to making
the final cell fate decision for differentiation into pDC or cDC
subsets.
PROINFLAMMATORY PROPERTIES OF FULLY
DIFFERENTIATED pDCs
pDCs represents a specialized subset of DCs that phenotypically
and functionally differs from cDCs. The primary function of
pDCs is the recognition of pathogen-associated molecular pat-
terns (PAMPs) such as viral single-strand RNA (through TLR7)
or bacterial CpG nucleotide DNA sequences (through TLR9) and
secretion of large amounts of IFN-I, IL-6, and TNF-α in response
to infection (Rogers et al., 2013) (Figure 2). However, pDCs are
also involved in the variety of other functions including support-
ing T cell survival, B cell differentiation (Shaw et al., 2010), cDC
activation, and coordinating effector T cell-mediated immune
responses against chronic infections (Cervantes-Barragan et al.,
2012). On the surface, human and mouse pDCs express a vari-
ety of markers and receptors, which distinguish them from
cDCs (Table 2). These molecules are involved in regulating key
pDC functions such as antigen sensing and presentation, pro-
duction of IFN-I, maturation, migration, adhesion and lineage
maintenance.
Mouse pDCs located in the spleen and liver express low
levels of TLR4 capable to sense muramyl dipeptide (MDP)
and other bacterial peptidoglycans and lipopolysaccharides
(Uehori et al., 2005). MDP recognition is accompanied with
increased expression of Nod2 (nucleotide-binding oligomeriza-
tion domain-containing protein 2; also known as Card15 or
Ibd1), the intracellular PAMP-recognizing receptor capable to
sense peptidoglycans (Kufer et al., 2006). TLR4 was shown to be
able detect not only bacterial pathogens but also recognize RNA
viruses and lead to increased production of IFN-I, autophagy, and
restricted virus replication (Kapoor et al., 2014).
In injury, the immune function of pDCs regulated by damage-
associated molecular patterns (DAMPs) including self-DNA (rec-
ognized by TLR4 and TLR9) and high mobility group box 1
(HMGB1) recognized by receptor for advanced glycation end-
products (RAGE) (Dumitriu et al., 2005; Bianchi, 2007). HMGB1
down-regulates TLR9-dependent capacity of pDCs to sense viral
and bacterial antigens and stimulate proinflammatory immune
responses mediated by T helper (Th)1 cells (Popovic et al., 2006).
The inhibitory function of HMGB1 could suggest for the activa-
tion of protective tolerogenic mechanism focused on maintaining
unresponsiveness of pDCs to self-antigens in the presence of
necrotic cell death.
IFNs-I comprise a growing family of IFN proteins includ-
ing IFN-α, IFN-β, IFN-δ, IFN-ε, IFN-κ, IFN-τ, IFN-ω, and
IFN-ζ (Hertzog and Williams, 2013). Among multiple members
of the IFN-I family, pDCs largely produce IFN-α and IFN-β,
which bind to the common IFN-α/β receptor consisted of two
chains (IFNAR1 and IFNAR2) (Uzé et al., 2007). Both compo-
nents of the IFN-α/β receptor start to express in CDPs (Robbins
et al., 2008). IFN-α supports terminal maturation and func-
tional commitment of pDCs via binding to the IFN-α/β recep-
tor (Luft et al., 1998; Korthals et al., 2007). IFN-α-dependent
activation of the receptor recruits non-receptor tyrosine-protein
kinases Tyk2 and Jak1 that phosphorylate several STAT mem-
bers. STAT1 and STAT2 complex to the heterodimer that binds
to IRF9 resulting in the formation of the heterotrimeric IFN-
stimulated gene factor 3 (ISGF3) (Pestka et al., 2004) (Figure 2).
The transcription complex translocates to the nucleus where
it primes expression of many IFN-I-inducible gene targets
including innate immune components such as TLR3, TLR7,
TLR9, IRF7, double strand viral RNA-sensing helicases (RIG-1,
MDA-5, and LGP-2), mitochondrial antiviral signaling protein
(MAVS), and stimulator of interferon gene (STING) (Platanias,
2005). IFN-α also induces expression of inflammasome-
forming components such as NOD-like receptor family, pyrin
domain-containing 3 (NLRP3), retinoic acid-inducible gene 1
(RIG-I), and CD69 (Malireddi and Kanneganti, 2013) and up-
regulates caspase-11 essential for activation of inflammasome
(Case et al., 2013).
IFN-I possess strong inflammatory properties by activating
the non-canonical NLRP3 inflammasome and contributing to
the inflammasome-dependent caspase-1 activation that leads to
proinflammatory pyroptotic cell death (Anand et al., 2011).
Pyropoptosis is associated with production of IL-1β and IL-
18 that increases the proinflammatory microenvironment in
infected and wounded tissues (Anand et al., 2011). pDCs also
contribute to inflammation by performing granzyme B- and
caspase-dependent cytotoxicity against target cells. The cytotoxic
properties of activated pDCs are up-regulated by IL-3 under
inflammatory conditions (Bratke et al., 2010). Finally, stimu-
lated pDCs produce increased levels of chemokines (CCL3, CCL4,
CCL5, CXCL9, and CXCL10) that attract inflammatory cells to
the inflamed sites (Sozzani et al., 2010).
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FIGURE 2 | Proinflammatory properties of plasmacytoid dendritic cells
(pDCs). pDCs are capable to sense a variety of pathogen-associated
molecular patterns (PAMPs) such as viral and bacterial peptides,
peptidoglycans, lipopolysaccharides (LPS), RNA, and DNA through a range of
pattern recognition receptors (PRRs) including Toll-like receptors (TLRs),
double strand RNA-sensing receptor helicases (PRK, RIG-1, MDA5, and
LGP2), and cytoplasmic receptors recognizing viral RNA and DNA (LRRFIPI,
cGAS, DAI, DDX, and DNA polymerase III) or peptides (NOD1 and NOD2).
TLR3, TLR7, TLR8, and TLR9 recognize pathogen-associated molecules in
intracellular exosomes. PAMP-induced activation of PRRs leads to the
activation of interferon-regulating factors IRF-3 and IRF-7 and transcription
factor NF-κB that drive transcription of Type I interferon (IFN) genes such as
IFN-α and IFN-β. In response to infection, pDCs secrete large amounts of
IFN-α and IFN-β that display a variety of stimulatory activities on innate and
adaptive immunity through activation of phagocytic and cytotoxic activities of
macrophages, antigen-presenting function of conventional DCs (cDCs) and
production of proinflammatory cytokines (interleukin(IL)-12, tumor necrosis
factor (TNF)-α, and IFN-γ. IFN-I-induced up-regulation of IFN-γ production by
natural killer (NK) cells and T cells is of great value since IFN-γ is a potent
antiviral agent. IFN-I also inhibit virus replication and invasion and arrest
bacterial proliferation. IFN-I is able to induce a positive feedback autocrine
response through binding to the IFN-α/β receptor (IFNAR) on the surface of
pDCs. The activation of the IFNAR leads to the recruitment of IRF9 that
forms a heterotrimeric transcription complex IGGF3 (IFN-stimulated gene
factor) capable to recognize specific regulatory motifs called
interferon-stimulated response elements (ISRE) in the promoter regions of
IFN-I-inducible target genes. As a result, many genes are expressed including
PRRS, chemokines, caspases, inflammasome (cryopyrin, Nlrp3), and
apoptotic cell surface death receptor Fas. Caspase-1 and caspase-11 are
required for the activation of inflammasome components and IL-1β. Release
of IL-1β and inflammasome induce death of infected cells through the
pypoptotic mechanism and activates inflammatory response. pDCs also
secrete IL-6 and TNF-α that activate cDCs and stimulate B cell differentiation
to antibody-producing cells. pDCs could display cytotoxic properties in an
IL-3-dependent manner. IL-3 produced by activated T cells could activate
signaling pathway mediated by signal transducers and activator of
transcription (STAT)3 and STAT5 and induce expression of granzyme B
(GZMB), whose release causes death of infected host cells.
TOLEROGENIC PROPERTIES OF pDCs
On the other hand, pDCs were shown to display promi-
nent tolerogenic and immunosuppressive activities (Figure 3).
Compared to cDCs, pDCs possess poor properties to stimu-
late T cells because they have a limited capacity to endocytosis
and express low surface levels of MHC class II, costimulatory
molecules, and cathepsins S and D essential for antigen process-
ing (Rogers et al., 2013). pDCs were found in the cortical and
medullar layers of the thymus where they play a role in inducing
and maintaining central tolerance. In mice, thymus-associated
tolerogenic pDCs are mainly of extrathymic origin. Like cDCs,
thymic pDCs acquire advanced ability to endocytose, process,
and present peripheral antigens to central tolerance. The antigen-
presenting capacity is enhanced through increased surface expres-
sion of CD8a, CD11c, and MHC class II (Hadeiba et al., 2012).
CCR9 and absence of TLR stimulation drives thymic migration
of pDCs and further homing in the thymus. CCR9+ pDCs are
potent inducers of regulatory T cells (Tregs) that are capable to
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Table 2 | Surface markers and receptors that distinguish human and mouse pDCs from cDCs.
Human pDC
markers/receptors
Function Mouse pDC
markers/receptors
Function
IL3Rα/CD123 Receptor for IL-3; supports terminal
differentiation, maturation, and maintenance of
pDCs
B220/CD45/PtprcC Negative regulator of cytokine receptor
signaling; regulation IFN-I production by pDCs
BDCA2/CLEC4A/CD303 Suppressing of TLR-9 mediated presentation
of bacterial antigens; inhibition of IFN-I
production
Siglec-H Delivery of viral antigens to pDCs; regulation
of IFN-I secretion through DAP-12
ILT7/LILRA4 Inhibition of production of IFN-I and
proinflammatory cytokines; binds BST-2
(CD317)
Bst-2/CD317/mPDCA-1 Viral antigen delivery; inhibition of virus release
from infected cells; interacts with the ligand,
ILT7/LILRA4
ILT3/LILRB4 Antigen binding and presentation; binds MHC
class I and inhibits activation of pDCs in
response to antigen recognition
LyQ49 Stimulation of pDC maturation and function;
activation of IFN-I production through
TLR9-dependent signaling; binds LyQ49 ligand
and MHC class I
LAIR1/CD305 Inhibition of pDC differentiation and function
including IFN-I production; binds complement
component c1q
Ly6C Transmission of signals for T cell activation and
cytokine production
BDCA4/NRP1 Regulation of cell adhesion and migration;
binds semaphorins and VEGF
PDC-TREM Regulation IFN-I production through DAP-12;
interacts with plexin-A1
FcγRIIa/CD32 Phagocytosis of opsonized bacteria Ly75/DEC205/CD205 Antigen delivery and presentation; recognition
of apoptotic and necrotic cells
CD36 Antigen internalization for presentation to T
cells
Lag-3/CD223 Regulation of pDC homeostasis;
down-regulation of T cell activation; binds
MHC class II
CD62L/L-selectin/SELL Antigen internalization for presentation to T
cells; attraction of pDCs and pDC precursors to
lymph nodes; homing of pDCs in lymph nodes
CD200R Induction of IDO production
IL-18R Receptor for IL-18; recruits pDCs in response
to inflammation
CCR9/CDw199 Regulation of homing of tolerogenic pDCs to
the gut; binds CCL25
CCR7 Control of pDC maturation; attraction of pDCs
to lymph nodes; homing of pDCs in lymph
nodes; binds CCL19 and CCL21
IL7Rα/CD132 Receptor for IL-7; regulates maintenance of
pDCs
TLR7 Recognition of viral single-strand RNAs;
induction of IFN-I production
TLR7 Recognition of viral single-strand RNAs;
induction of IFN-I production
TLR9 Recognition of bacterial unmethylated CpG
sequences; induction of IFN-I and IL-12
production
TLR9 Recognition of bacterial unmethylated CpG
sequences; induction of IFN-I and IL-12
production
CCR5 Recruitment of pDCs in response to
inflammation; binds CCL3, CCL4, CCL5, and
CCL3L1
CXCR3 Recruitment of pDCs in response to viral
infection and IFN-γ-mediated immunity; binds
CXCL4, CXCL9, CXCL10, and CXCL11
BDCA2, Blood dendritic cell antigen 2; Bst-2, Bone marrow stromal cell antigen 2; DAP-12, DNAX-activating protein 12; DEC205, dendritic and epithelial cells,
205 kDa; FcγRIIa, Low affinity immunoglobulin-γ Fc region receptor IIa; IDO, indoleamine 2,3-dioxygenase; ILT7, Immunoglobulin-like transcript-7; Lag-3, Lymphocyte-
activation gene 3; LAIR1, Leukocyte-associated immunoglobulin-like receptor 1; LILRA4, Leukocyte immunoglobulin-like receptor A4; MHC, Major histocompatibility
complex; mPDCA-1, mouse plasmacytoid dendritic cell antigen-1; NRP1, Neurophilin 1; PDC- SELL, L-selectin; TREM, Plasmacytoid dendritic cell-specific receptor;
PtprcC, Protein tyrosine phosphatase, receptor type C; VEGF, vascular endothelial growth factor.
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FIGURE 3 | Tolerogenic properties of plasmacytoid dendritic cells (pDCs).
pDCs utilize several molecular mechanisms to induce tolerogenic properties.
When phosphorylated, indoleamine-pyrrole 2,3-dioxygenase (IDO), an
enzyme catabolizing L-tryptophan to N-formylkynurenine acquires potent
immunomodulatory properties. IDO promotes differentiation of naïve T cells
to inducible CD4+ and CD8+ regulatory T cells (Tregs) through cytotoxic
T-lymphocyte antigen 4 (CTLA4)/CD80 pathway. In pDCs, IDO expression
could be induced by multiple mechanisms including interferon (IFN)-γ-, IFN-α-,
and transforming growth factor (TNF)-β-dependent pathways. Transcription
factors Foxo and FoxP3 also stimulate IDO production. Kynurenine, a product
of the IDO-catalyzed reaction can up-regulate IDO via a positive autocrine
feedback mediated by the aryl-hydrocarbon receptor (AhR). IDO can
up-regulate expression of the immunosuppressive molecule PD-L1
(programmed death-ligand 1) on the surface of pDCs. PD-L1 interaction with
the PD-1 molecule decreases proliferation of the target T cell. Stimulation of
the Toll-like receptor (TLR)-9 with CpG oligonucleotides leads to the activation
of PD-L1 and induces expression thymic stromal lymphopoietin (TSLP)
receptor on the surface of pDCs. The TSLPR is essential to mediate
stimulatory effects of TSLP produced by Hassall’s corpuscles on
pDC-mediated differentiation, maturation, and expansion of immature
thymocytes to CD4+CD25+FoxP3+ Tregs and promoting central tolerance.
TSLP-activated pDCs produce chemokines CCl17 and CCL21 essential for
attraction of thymocytes to the thymic medulla. TSLP-induced pDCs drive
maturation of Tregs that produce more IL-10 and less TGF-β. On the surface,
pDCs express unstable antigen-Major Histocompatibility Complex (MHC)
class II due to up-regulated membrane-associated MHC II ubiquitin E3 ligase
MARCH-I that promotes rapid turnover and degradation of antigen-presenting
complexes and supports maturation of Tregs. Finally, IL-3 could activate
expression of granzyme B in pDCs, and its release suppresses proliferation of
effector T cells.
suppress antigen-specific immune responses both in vitro and
in vivo (Hadeiba et al., 2008). However, compared to Sirpα+
cDCs and CD8α+ cDCs, pDCs were shown to be less efficient
in the presentation of blood-borne antigens followed with neg-
ative selection of T cells and induction of Tregs (Atibalentja et al.,
2011). Martín et al. (2002) characterized population of mouse
thymic CD8α+B220+ pDCs with regulatory properties capable
to induce Tregs that further suppressed antigen-specific T-cell
proliferation. Upon stimulation with artificial microbial antigens
(CpG oligonucleotides, poly I:C), these cells were able to differen-
tiate to potent APCs producing IFN-I, IL-10, and IL-12 (Martín
et al., 2002).
In humans, thymic resident pDCs were shown to induce
natural FoxP3+CD4+CD25+ Tregs (nTregs) from thymic pre-
cursors in a CD40/CD40L-dependent manner (Martín-Gayo
et al., 2010). pDC-induced nTregs preferentially produced anti-
inflammatory cytokine IL-10 while cDC-induced nTregs were
better TGF-β producers. Indeed, the CD40/CD40L-dependent
signaling may play a central role in induction of tolerogenic
immunoregulatory pDCs in both humans andmice (Kumanogoh
et al., 2001). nTreg precursors stimulate CD40L on T-cell receptor
(TCR) engagement and induce maturation of pDCs. Therefore,
CD40-CD40L-mediated crosstalk between pDCs and self-reactive
nTreg precursors may provide critical feedback signals required
www.frontiersin.org July 2014 | Volume 5 | Article 279 | 9
Chistiakov et al. Dendritic cells and atherogenesis
for pDC maturation and nTreg differentiation in the steady-state
human thymus (Martín-Gayo et al., 2010).
Thymus-specific structures formed by epithelial reticular
cells in human and murine thymic medulla called Hassall’s
corpuscles were shown to secrete thymic stromal lymphopoi-
etin (TSLP), a hemapoietic growth factor that is involved in
pDC-induced generation of nTregs (Watanabe et al., 2005).
TSLP up-regulates CD80/CD86 in thymic CD11c+ DCs that
became able to drive secondary positive selection of self-reactive
CD4+CD8−CD25− T cells to forkhead box P3 (FoxP3)+ nTregs.
The TSLP-dependent mechanism of generating nTregs involves
TLR7- and TLR9-mediated induction of the TSLP receptor
and IL-7Rα in pDCs that start to secrete chemokines CCL17
and CCL22 guiding the traffic of developing immature thymic
T cells into the medulla (Hanabuchi et al., 2010). TLR9 stim-
ulation with CpG oligonucleotides is shown to play a key role
in pDC-mediated induction of both thymic and peripheral
FoxP3+CD4+CD25+ Tregs (Moseman et al., 2004). Interestingly,
TSLP-induced pDCs support generation of IL-10-producing
nTregs while TSLP-induced cDCs contribute to preferential dif-
ferentiation of TGF-β-producing Tregs. The two subsets of nTregs
could be distinguished not only by cytokine production but pres-
ence/absence of inducible T-cell costimulator (ICOS). The ICOS+
nTregs subset had the potential to express high IL-10 and less
TGF-β (Ito et al., 2008). Therefore, thymic pDCs and cDCs are
able to induce distinct subsets of nTregs.
In the periphery, antigen-stimulated pDCs were found to sup-
port differentiation of naïve CD4+ T cells to effector T cells
producing high levels of anti-inflammatory IL-10 and IFN-γ
(Kvale et al., 2007) or to cytotoxic CD4+ T cells with regu-
latory properties (Kawamura et al., 2006) in order to prevent
unfavorable inflammatory response and induce mucosal toler-
ance to ingested (gut) or inhaled (airways) antigens. Murine liver
pDCs induce antigen-specific suppression of CD4+CD8+ T cell
responses mediated by deletion or anergy (Mann et al., 2013).
Peripheral pDCs also induce various tissue-specific Treg sub-
sets (for example, such as tonsilar CD4+CD25+CD127−FoxP3+
Tregs (Palomares et al., 2012) from naïve T cells responsible
for maintaining peripheral tolerance. pDC also imprint specific
homing properties on T cells that they stimulate enabling T-cell
migration back to home sites (Lombardi and Khaiboullina, 2014).
pDCs utilize several immunosuppressive tolerogenic molec-
ular mechanisms including induction of indoleamine-pyrrole
2,3-dioxygenase (IDO), an enzyme catabolizing L-tryptophan to
N-formylkynurenine (Fallarino et al., 2007; Kahler and Mellor,
2009). This enzyme possesses immunomodulatory (immuno-
suppressive) properties by removing the essential amino acid
tryptophan from the cellular microenvironment (Mellor, 2005).
In pDCs, IDO could be induced through non-canonical NF-
κB signaling by CD200-Ig-dependent stimulation of CD200
receptor (CD200R) with the involvement of the IFN-α/β recep-
tor signaling (Fallarino et al., 2004), IFN-γ-mediated feedback
(with induction of the IDO enzymatic function), and in a
TGF-β-dependent manner (with induction of the IDO regu-
latory function) (Fallarino et al., 2012). IFN-γ was shown to
induce the IRF-8-mediated expression of IDO associated with
down-regulation of DAP-12, a negative regulator of the IDO
production (Orabona et al., 2005, 2006). Once phosphorylated,
IDO mediates signaling events culminating in self-amplification
and maintenance of a stably regulatory condition in pDCs
(Heitger, 2011). IDO promotes differentiation of naïve CD4+
T cells to Tregs by stimulating CD40/CD40L-mediated signal-
ing through cytotoxic T-lymphocyte antigen 4 (CTLA4)/CD80,
CD40/CD40L, and glucocorticoid-induced tumor necrosis fac-
tor receptor (GITR)/CITR ligand mechanisms (Fallarino et al.,
2005). A positive feedback loop mediated by kynurenine through
the aryl-hydrocarbon receptor (AhR) on the surface of pDCs
and stimulatory signals from Tregs are required for maintenance
of IDO-dependent tolerogenic properties of pDCs (Harden and
Egilmez, 2012).
By down-regulating membrane-associated MHC II ubiquitin
E3 ligase MARCH-I, cDCs were shown to form stable com-
plexes between antigenic and MHC class II molecules on their
surface upon activation (De Gassart et al., 2008; Ohmura-
Hoshino et al., 2009) that supports the long-term antigen-
presenting function. In contrast, activated pDCs failed to inhibit
MARCH-I that results in formation of continuously ubiquiti-
nated, internalized, and unstable antigen-MHC class II complexes
on their surface (Young et al., 2008). Since low antigen lev-
els (and low TCR stimuli) were found to promote development
of Tregs (Turner et al., 2009; Molinero et al., 2011), the rapid
turnover of antigen-MHC class complexes on the surface of pDCs
underlines their limited antigen-presenting ability and there-
fore supports low antigen levels, which in turn should stimulate
MARCH-I-mediated induction and functional activity of Tregs
(Ishido et al., 2010).
Another pDC-mediated immunosuppressive mechanism
involves up-regulation of the surface expression of programmed
death-ligand 1 (PD-L1), an immunoinhibitory molecule (Keir
et al., 2007). Interaction between PD-1 and its ligand PD-L1
promotes tolerance by blocking the TCR-induced stop signal in
the target T cell (Fife et al., 2009). IL-27 was shown to initiate
PD-L1 expression in pDCs in a STAT3-dependent manner
thereby inducing their immunosuppressive properties and
limiting the potential to stimulate naïve T cells (Karakhanova
et al., 2011). Mouse liver pDCs were shown to express high levels
of IL-27 and IL-27 receptor, which are essential for induction of
PD-L1-dependent tolerogenic properties of pDCs (Matta et al.,
2012).
Indeed, these data clearly show that pDCs could display proin-
flammatory and immunosuppressive tolerogenic properties. The
local microenvironment and extrinsic stimuli influence pDC
phenotype and hence could control the phenotypic switch
toward inflammation or tolerance. pDCs were shown to
be involved in advanced inflammatory response in several
autoimmune proinflammatory diseases including multiple scle-
rosis, inflammatory bowel disease, psoriasis, and systemic lupus
erythematosus (von Glehn et al., 2012). On the other hand,
pDCs drive development of Tregs and mediate immunosup-
pression and tolerance in graft-versus-host disease (Rogers
et al., 2013) and some cancers (Johnson and Ohashi, 2013).
Atherogenesis was shown to involve many types of immune
cells that display a variety of activities in supporting or sup-
pressing atherosclerosis-associated inflammation. Among those,
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pDCs play a non-redundant role in atherogenesis (Döring and
Zernecke, 2012; Alberts-Grill et al., 2013; Ait-Oufella et al., 2014;
Busch et al., 2014; Subramanian and Tabas, 2014; Zernecke,
2014).
PROINFLAMMATORY ACTIVITIES OF pDCs IN
ATHEROSCLEROSIS
pDCs were found to be colocalized with T cells in atherosclerotic
plaques in humans (Yilmaz et al., 2004; Bobryshev, 2010) and
mice (Jongstra-Bilen et al., 2006) preferentially in the unstable
shoulder region (Yilmaz et al., 2004; Niessner et al., 2006). Close
proximity of pDCs to T cells in plaque areas, containing immune-
inflammatory infiltrates, is indicative that the functional contacts
between pDCs and T cells might be formed directly in situ in
atherosclerotic arteries (Figure 4).
There are some conflicting results regarding the changes in
pDC numbers during atherosclerosis progression. Some studies
reported unchanged counts of pDCs in patients with coronary
artery disease (CAD) (Shi et al., 2007) and myocardial infarc-
tion (MI) (Wen et al., 2013). Other researchers detected decreased
numbers of pDCs in patients with troponin-positive unstable
coronary artery syndromes (Van Vré et al., 2006), end-stage
heart disease (Athanassopoulos et al., 2004), and advanced CAD
(Yilmaz et al., 2009; Van Vré et al., 2010). Furthermore, an inverse
correlation between the severity of CAD and pDC numbers was
observed (Yilmaz et al., 2009; Van Brussel et al., 2011). Decrease
in pDC levels observed in acute coronary events could reflect
increased recruitment of pDCs in supporting advanced pron-
flammatory responses preceding the acute cardiovascular event
(Sorrentino et al., 2010). There were no significant changes in
numbers of circulating pDC precursors in CAD patients (Wen
FIGURE 4 | Immunohistochemical visualization of close proximity of
pDCs (rose) to T cells (brown) in an area of human aortic
atherosclerotic plaque containing immune-inflammatory infiltrate.
Double immunostaining: pDCs were visualized using anti- BDCA-2 antibody
(CD303; Miltenyi Biotec) while T cells were visualized using anti-CD3
antibody (Dako). A combination of peroxidase-antiperoxidase and alkaline
phosphatase-antialkaline phosphatase immunotechniques using
3-Amino-9-ethylcarbazole (AEC) substrate and diaminobenzidine (DAB).
Magnification: ×400.
et al., 2013) although concentration of pDC attractants such as
CCL2, CCL5, CXCL12, E-selectin, and P-selectin is increased in
atherosclerotic vessels (Peter et al., 1997; de La Rosa et al., 2003;
Erbel et al., 2007).
In atherosclerosis, pDC function is impaired. Plaque tissues
of patients with ischemic complications (and shoulder regions
especially) expressed higher levels of CD83 (Siglec), a marker
of DC activation (Erbel et al., 2007). However, Van Brussel
et al. (2011) showed that pDCs derived from CAD patients
expressed lower levels of CD83 and TLR7 and as a consequence
produced less IFN-α. Similarly, decreased expression of proin-
flammatory cytokines (IL-1β and IL-6) was observed in type
2 diabetic patients with atherosclerotic complications (Corrales
et al., 2007).This may suggest for impaired function of atheroscle-
rotic pDCs that become more resistant to multiple proinflam-
matory stimuli present in the plaque. Otherwise, this may be
a consequence of the negative autocrine regulatory feedback of
IFN-α (Malireddi and Kanneganti, 2013).
Modified lipoproteins are considered to be one of the major
inducers and mediators of atherosclerosis-related inflammation.
Oxidized low density lipoproteins (oxLDL) were shown to prime
differentiation and maturation of cultured pDC precursors to
cDCs and pDCs in vitro (Nickel et al., 2009) suggesting for
possibility of oxLDL-driven proatherosclerotic differentiation of
pDC precursors in vascular inflammation. The oxLDL-dependent
DC differentiation is mediated by scavenger receptors such as
CD36 and CD205 whose expression is up-regulated. CD36 is
a principal receptor that is involved in oxLDL uptake by DCs
and macrophages (Kunjathoor et al., 2002). In atherosclerosis,
pDCs could be also activated with a variety of antigens such
as self-DNA, antimicrobial peptide Cramp/LL37 (Döring et al.,
2012), and CpG oligonucleotides (Niessner et al., 2006). Self-
antigens are able to form circulating immune complexes with self-
antibodies that possess advanced atherogenic properties through
stimulation of T-cell-mediated proinflammatory responses. Self-
DNA can form complexes with LL37, which then activate IFN-
α production by pDCs through the TCR9-mediated signaling
(Lande et al., 2007).
Activated pDCs were shown to support atherosclerosis pro-
gression by elevated production of proinflammatory IFN-α
(Niessner et al., 2006). In bothmouse atherosclerosis models [e.g.,
animals deficient for apolipoprotein E (ApoE) or LDL receptor
(Ldlr)], treatment with IFN-I enhanced atherogenesis associated
with increase in lesion numbers and plaque size, macrophage-
endothelial cell adhesion, and leukocyte attraction to inflamed
vascular sites (Levy et al., 2003; Goossens et al., 2010). In
ApoE-deficient mice, specific depletion of pDCs with mPDCA-1
antibody had the atheroprotective effect by reducing accumula-
tion of macrophages in plaques and T-cell activation, decreasing
production of proinflammatory cytokines (IL-12, IFN-γ) and
chemokines (CXCL1, CXCL10), increasing plaque fibrosis, and
implying a more stable lesion phenotype (Macritchie et al., 2012).
In humans, pDC-mediated secretion of IFN-α led to the proin-
flammatory activation of cDCs that is reflected by up-regulated
TLR4-mediated production of a set of inflammatory cytokines
(IL-12, IL-23, and TNF-α) (Niessner et al., 2007). In addition,
IFN-α induced increased IFN-γ secretion and up-regulation of
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TNF-related apoptosis-inducing ligand (TRAIL) in effector T
cells (Niessner et al., 2006). TRAIL-positive CD4+ T cells were
shown to kill vascular smooth muscle cells (VSMCs) in the
atherosclerotic plaque via the TRAIL/DR5-dependent apoptotic
mechanism (Pryshchep et al., 2006; Sato et al., 2006). Indeed,
pDC-induced activation of atherogenic cytotoxic T cells could
cause VSMC apoptosis, a process that could lead to plaque
destabilization and increase risk of acute coronary syndrome.
Human pDCs were shown to possess cytotoxic properties by
IL-3-dependent releasing granzyme B that kills endothelial cells
(Bratke et al., 2010).
TOLEROGENIC AND IMMUNOSUPPRESSIVE PROPERTIES OF
pDCs IN ATHEROSCLEROSIS
Recently, Daissormont et al. (2011) showed atheroprotective
properties of pDCs in in Ldlr-deficient mice. Targeted deple-
tion of pDCs with a Bst-2-specific antibody aggravated athero-
genic progression associated with increased T cell accumulation
in plaques and elevated IFN-γ production. The depleted pDC
population showed tolerogenic and anti-inflammatory properties
via the IDO-dependent mechanism since IDO inhibition dis-
rupted the immunosuppressive effect of pDCs. In addition to
IDO, tolerogenic pDCs could involve other immunosuppressive
mechanisms such as PD1/PD-L1 (Tokita et al., 2008) and IL-
3-mediated granzyme B production to suppress proliferation of
effector T cells (Jahrsdörfer et al., 2010). It appears that only cer-
tain pDC subsets including immature and tissue-specific pDCs
(Ochando et al., 2006; Hadeiba et al., 2008) or pDC precur-
sors (MacDonald et al., 2005; Huang et al., 2011) could exhibit
immunoregulatory properties and support induction of T regs.
In murine atherosclerotic plaques, tolerogenic pDCs are scarcely
presented (Daissormont et al. (2011). However, they are able to
influence significantly the atherosclerotic progression.
Interestingly, atheroprotective tolerogenic pDCs could be
induced by self-peptides such as an ApoE-derived peptide Ep1.B
(Bellemore et al., 2014) or with bacterial antigens such as
Mycobacterium bovis BCG (a causative agent of tuberculosis)
killed by extended freeze-drying (BCG EFD) (Ovchinnikova et al.,
2014). The ApoE peptide Ep1.B corresponds to C-terminal amino
acids 239-252 of the human ApoE molecule and is atheroperotec-
tive itself (Stephens et al., 2008). When injected to the mice, the
peptide was shown to induce molecular and phenotypic changes
in pDCs inducing tolerogenic properties associated with plaque
degradation, diminished IFN-γ production and proliferation of
T cells, activation of IL-10 secretion, and generation of Treg cells
(Bocksch et al., 2007). Similar anti-atherosclerotic effects were
reached with pDCs induced with Ep1.B and BCG EFD including
induction of IL-10-producing Tregs (Ovchinnikova et al., 2014).
Tolerogenic pDCs are likely to drive development of inducible
Tregs in draining lymph nodes followed with expansion of Tregs
but not tolerogenic pDCs in spleen.
These experiments provide a prominent promise for using
tolerogenic pDCs for development of cost-effective atheropro-
tective vaccines based on available immunogenes such as BCG
EFD.However, DC-based anti-atherosclerotic immunization pro-
tocols have been only recently employed and much more
should be done in developing efficient vaccination strategies
for atherosclerosis. One of the advances in developing effective
vaccines for atherosclerosis is the selection of a specific anti-
gen to target. The ApoE peptide Ep1.B could represent such an
antigen that is beneficial for obtaining tolerogenic pDC-based
atheroprotective vaccines.
CONCLUSION
Thus, pDCs influence the development of atherosclerosis in both
ways, by contributing to proatherogenic vascular inflammation
and by suppressing inflammatory responses through induction
of self-tolerogenic properties and Tregs. It is likely that pDCs
preferentially exhibit the proinflammatory phenotype at early
atherosclerosis stages. At initial steps of lesion formation, pDCs
activated by proinflammatory stimuli produce proatherogenic
IFN-I and trigger T cell activation and T cell-mediated immune
responses including generation of inducible Tregs. In advanced
atherosclerotic lesions, pDCs could acquire tolerogenic properties
and delay the development of atherosclerosis. However, to verify
this hypothesis, sequential observations of quantitative and qual-
itative changes in the function and phenotype of pDCs during
atherosclerosis progression are required.
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